Last reviewed · How we verify
NCT04852731: STAMP-2
STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2
NA trial testing Cardiac MRI in Mitral Valve Prolapse in 280 participants. Currently enrolling.
1 July 2027
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 280 |
| Start date | 30 August 2021 |
| Primary completion | 1 July 2027 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Cardiac MRI
- Blood collection — full drug profile →
- Prolongation of the MRI examination
Conditions studied
- Mitral Valve Prolapse — all drugs for Mitral Valve Prolapse →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Mitral Valve Prolapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mitral valve prolapse (MVP) is a frequent affection of the mitral valve with a prevalence of 2-3% in the general population. This valvular disease is generally considered as benign, but may at term evolve toward mitral valve regurgitation of various severity and/or arrhythmia. Mitral valve prolapse is routinely diagnosed using transthoracic echocardiography. Subsequent examinations (24-hour external loop recording, exercise electrocardiogram, cardiac Magnetic Resonance Imaging) and a close follow-up can be proposed to the patient depending on its condition. More recently, detection of myocardial fibrosis and a mitral ring disjunction among patients with MVP were associated with the occurrence of severe ventricular arrhythmia. The investigators hypothesize that ventricular remodeling over time is mediated by the progression of mitral insufficiency severity from myocardial fibrosis secondary to MVP and possibly promoted by other mitral valve abnormalities. This remodeling, characterized by circulating biomarkers and imaging (MRI and echocardiography), could allow the identification of patients with a higher risk of severe ventricular arrhythmia. The main objective of this study is to identify prognostic factors for unfavorable evolution (ventricular remodeling or a rhythm disorder event) at 3 years from initial assessments in MVP patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04852731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiac MRI
Trials testing the same drug.
- NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
- NCT06814990 — Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and T · NA · recruiting
- NCT06278519 — CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE) · NA · active not recruiting
- NCT07027683 — Cardiac Magnetic Resonance for Diagnosing and Guiding Treatment in Concealed Myocardial Rupture · enrolling by invitation
- NCT05930418 — Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis · NA · active not recruiting
Other recruiting trials for Mitral Valve Prolapse
Currently open trials in the same condition.
- NCT07366723 — The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation · NA · active not recruiting
- NCT06255457 — Ventricular Arrhythmias in Patients Undergoing Mitral Valve Surgery · recruiting
- NCT07103733 — PRIMARY Ancillary Substudy · NA · recruiting
- NCT06738537 — Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse · recruiting
- NCT06341166 — Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04852731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 9 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04852731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing